世界の標的アルファの情勢をしるには国際シンポジウムを覗くのがよさそうだ。
なかに発表のpower point があるようだ。
Tuesday, April 2, 2019
Please note that PDF versions of PowerPoint files presented during TAT 11 are included only where permission to do so was provided by the speaker. Click on the name of the presentation to download the pdf file.
Opening Session
Pretargeted Ac-225 Radiommunotherapy Strategies
Dr. Jason S. Lewis, Vice Chair for Research, Chief of the Radiochemistry and Imaging Sciences Service, and Director of the Radiochemistry and Molecular Imaging Probe Core Facility, Memorial Sloan Kettering Cancer Center
Contribution of Targeted and Off-target Effects during Radionuclide Therapy using High-LET Particles
Dr. Jean-Pierre Pouget, Head, Radiobiology and Targeted Radiotherapy Team, Institut de Recherche en Cancérologie de Montpellier
...
Ac-225 Preclinical
Highly Effective Treatment of CD38 Positive Experimental Lymphoma with Actinium-225-Daratumumab
Dr. Wojciech Dawicki, University of Saskatchewan
Ac-225-labeled Girentuximab for Targeted Alpha Therapy of CAIX-expressing Renal Cell Cancer Xenografts
Mr. Robin Merkx, Radboudumc, Nijmegen
Radiometals Preclinical
IGFR-1 Targeted Alpha Therapeutic FPI-1434 Causes DNA Double-stranded Breaks and Induces Regression in Preclinical Models of Human Cancer
Dr. Eric Burak, Fusion Pharmaceuticals
Combining Bismuth-213 with Nanobodies: Finding the Perfect Match for Targeted Alpha Therapy
Ms. Yana Dekempeneer, Studiecentrum voor Kernenergie (SCK-CEN)
212Pb-NNV003 as a Novel Targeted Alpha Therapy for CD37 Positive B-cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)
Dr. Amal Saidi, Orano Med
Other Radionuclides
The Use of Albumin Binders as a Strategy to Optimize Tumour Delivery of Therapeutic Radioisotopes
Dr. Kuo-Shyan Lin, Senior Scientist, BC Cancer, Department of Molecular Oncology, and Associate Professor, the University of British Columbia, Department of Radiology
Radiohalogenated Neopentyl Derivatives: A Novel Scaffold for Radioiodinated and Astatinated Compounds of High Stability to In Vivo Dehalogenation
Dr. Hiroyuki Suzuki, Chiba University, Graduate School of Pharmaceutical Sciences
Tuning of the Radium Biodistribution by Dietary Supplements in a CD1 Mice Model
Dr. Ján Kozempel, Czech Technical University in Prague
Preclinical in Vitro Nanocarriers/Safety, Regulation
Nanoparticles for the Treatment of Metastatic Non Small Cell Lung Cancer with Ac-225
Dr. Charles Maitz, University of Missouri, College of Veterinary Medicine and Surgery
Consideration toward Safety Guidance for Targeted Alpha Therapy in Japan
Prof. Tsuneo Yano, Osaka University, RCNP
The Role of the IAEA in the Development of Radiopharmaceutical Sciences with Focus on Alpha Emitters
Dr. Amirreza Jalilian, International Atomic Energy
Wednesday, April 3, 2019
Opening Sessionç
Radiochemistry
New Bifunctional Chelators for Ac-225 and 227Th Radioimmunotherapy
Ms. Lily Li, University of British Columbia
Various Chromatographic Schemes for Separation of 213Bi from Ac-225
Dr. Aleksandr Vasiliev, Institute for Nuclear Research of Russian Academy of Sciences
Evaluation of Inorganic ion Exchange Materials for Purification of Ac-225 from Thorium and Radium Radioisotopes
Mr. Jonathan Fitzsimmons, Brookhaven National Lab
Evaluation of Specific activity and Stable Impurities in Ac-225 Derived from ISAC and 229Th Decay
Ms. Jenasee Mynerich, TRIUMF, McMaster University